Two doses of Pfizer AstraZeneca Covid vaccines generate lower levels of antibodies against the Omicron variant of coronavirus.
The company said it has initiated engagements with Indian health authorities regarding its Covid prevention drug for people with weakened immune system
The US Food and Drug Administration (FDA) has granted emergency use authorisation to AstraZeneca's monoclonal antibody treatment for Covid-19 among people with weakened immune systems.
South Korean biopharmaceutical firm SK Bioscience's IPO raised $1.3 billion for the firm, which is a local Covid-19 vaccine-production partner with AstraZeneca Plc.
Future pandemics could be even more lethal than Covid so the lessons learned from the pandemic must not be squandered, one of the creators of the Oxford-AstraZeneca vaccine said.
The UK drugmaker's opposition meant the offer fell short of the 90 per cent threshold needed for approval
Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines.
Vaccines are effective in decreasing hospitalization and deaths from Covid-19 infection but the emergence of viral variants of concern may diminish their efficacy, according to a recent study.
Two linked cases of the new Omicron coronavirus variant have been detected in Britain connected to travel to southern Africa, health minister Sajid Javid said on Saturday
The company has also developed an antibody cocktail which can be used both to prevent and to treat Covid-19
The first batches of Covishield left the SII manufacturing facility in Pune earlier today, for distribution to low- and middle-income countries
Soriot was speaking as his company unveiled a major state-of-the-art research and development facility in Cambridge
Prince Charles will be on hand Tuesday when pharmaceutical company AstraZeneca opens a 1 billion-pound research centre near the University of Cambridge
The treatment is given in one go, as two sequential shots in the arm
The Oxford/AstraZeneca vaccine has until now been sold on a not-for-profit basis
British-Swedish pharmaceutical company AstraZeneca said Friday that it will start to book a modest profit from its coronavirus vaccine as it moves away from the nonprofit model
The drug firm on Tuesday reported a 54.65 per cent decline in its net profit
People who receive the Pfizer or AstraZeneca COVID-19 vaccine have antibody levels significantly higher than those infected with the SARS-CoV-2 virus, according to a study
AstraZeneca said Thursday that it is withdrawing its application for approval of its COVID-19 vaccine in Switzerland because the country's medical regulator wanted to restrict its use to people over age 50. Switzerland has cleared the BioNTech-Pfizer, Moderna and Johnson & Johnson vaccines for use. However, national medical regulator Swissmedic hadn't yet granted marketing authorization for the AstraZeneca vaccine. The British-Swedish pharmaceutical company said that, since it started rolling submissions for authorization in Switzerland in October 2020, it has been in close communication with the regulator and has continuously provided the requested study results and other pertinent information and documents. AstraZeneca said it has now decided not to pursue the marketing authorization for its COVID-19 vaccine in Switzerland. This decision is based on Swissmedic's requirement to restrict the indication to people 50 years and above. Swissmedic acknowledged AstraZeneca's decision in
Johnson made the announcement as he arrived in Rome for a summit of Group of 20 leaders